To study outcomes in patients of relapsed and cancer that has spread to other body parts or organs in carcinoma of cervix, post chemotherapy treatment.

Not yet recruiting

Conditions: Malignant neoplasm of cervix uteri,

Registration Number: CTRI/2021/12/038486

Lead Sponsor: Tata Memorial Centre

Brief Summary: **Study Methodology**

Study area: Gynaecology oncology disease management group, Tata Memorial Centre, Mumbai.

Study population: Metastatic stage IV B cervical cancer patients / recurrent cervical cancer patients who have recurrent or progressive disease planned for palliative intent of treatment.

Study period: January 2015 to March 2021.

Sample size: All patients in the above time period

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: Female

Target Recruitment: 1000

Inclusion Criteria

Age >18 years with histopathologically confirmed upfront metastatic cervical patients or patients with cervical cancer who have become metastatic/recurred/progressed after prior concurrent chemo radiation or radiation.

Exclusion Criteria

Oligometastatic cervical cancer patients who are planned for treatment with curative intent.
Patients treated with palliative radiotherapy only.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To estimate the progression-free survival, PFS of metastatic or recurrent cervical cancer patients treated with palliative systemic therapy in our institute from January 2015 to March 2020. The PFS will be from the date of start of palliative treatment till the date of progression	To estimate the progression-free survival, PFS of metastatic or recurrent cervical cancer patients treated with palliative systemic therapy in our institute from January 2015 to March 2020. The PFS will be from the date of start of palliative treatment till the date of progression

Secondary Outcome Measures

Name	Time	Method
I.To estimate the Overall tumour response rates including stable disease, partial response, complete response and progressive disease.	II.Toxicities of therapy: To study the toxicities and tolerance to chemotherapy/bevacizumab/immunotherapy.

Trial Locations

Locations (1): Tata Memorial Centre
🇮🇳
Mumbai, MAHARASHTRA, India
Tata Memorial Centre
🇮🇳Mumbai, MAHARASHTRA, India
Dr Sushmita Rath
Principal investigator
02224177201
sushmitarath73@gmail.com